Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma stud

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

More... (http://www.news-medical.net/news/20120928/Provectus-amends-and-expands-protocol-for-PV-10-Phase-1-hepatocellular-carcinoma-study.aspx)